EGFR

EGFR
Name	Epidermal growth factor receptor
Uniprot	P00533
Chromosomal location	7p11.2
Length	~1,210 aa (precursor)

EGFR Epidermal growth factor receptor is a transmembrane receptor tyrosine kinase implicated in cell proliferation, differentiation, migration, and survival. First characterized in studies involving Stanley Cohen, Herbert S. G. Schaller, and biochemical work at Washington University in St. Louis, EGFR has since been central to research at institutions such as Massachusetts Institute of Technology, Johns Hopkins University, Stanford University, and University of California, San Francisco. Major projects at organizations including the National Institutes of Health, European Molecular Biology Laboratory, and Wellcome Trust Sanger Institute expanded understanding of EGFR in contexts ranging from basic science to clinical oncology at hospitals like Mayo Clinic and MD Anderson Cancer Center.

Introduction

EGFR was identified through ligand-binding studies using ligands such as Epidermal growth factor and research by Stanley Cohen who received the Nobel Prize in Physiology or Medicine. Structural and functional characterization involved groups at Cold Spring Harbor Laboratory and the Max Planck Society. EGFR signaling intersects with pathways studied by researchers at Harvard Medical School, Yale University, and University of Cambridge, and it figures in reviews from journals like Nature, Science, Cell, The Lancet, and New England Journal of Medicine.

Structure and isoforms

The EGFR protein comprises an extracellular ligand-binding domain, a single-pass transmembrane helix, an intracellular tyrosine kinase domain, and regulatory C-terminal tail; high-resolution structures were solved by teams at European Synchrotron Radiation Facility and Diamond Light Source. X-ray crystallography and cryo-EM work from labs at UCSF and EMBL revealed conformations studied alongside proteins like HER2, HER3, and HER4. Alternative splicing and post-translational modifications produce isoforms discussed in datasets from UniProt, Ensembl, and GenBank and analyzed in consortiums such as the International Cancer Genome Consortium and The Cancer Genome Atlas. Glycosylation patterns were mapped with mass spectrometry platforms developed at Stanford University and ETH Zurich.

Biological function and signaling pathways

Ligand binding activates EGFR dimerization and autophosphorylation, initiating cascades involving RAS, RAF1, MEK, ERK1/2, PI3K, AKT1, mTOR, STAT3, and SRC. Crosstalk with receptors like MET (hepatocyte growth factor receptor), IGF1R, and VEGFR integrates signals described in reviews from Cell Metabolism and Nature Reviews Cancer. Downstream transcriptional programs engage factors including MYC, FOS, JUN, and E2F, and are modulated by ubiquitin ligases such as CBL and endocytic machinery involving CLATHRIN and RAB5. Signaling dynamics have been modeled using frameworks from researchers at Princeton University, University of Oxford, and California Institute of Technology.

Role in development and homeostasis

EGFR activity is essential in organogenesis of tissues like epidermis, lung, liver, and brain; developmental genetics studies by laboratories at University of Pennsylvania and University of Chicago used knockout models paralleling observations in Drosophila melanogaster and Mus musculus. Homeostatic functions include wound healing and stem cell regulation mediated via interactions with morphogens studied by groups at Salk Institute, Karolinska Institutet, and Riken. EGFR signaling influences processes regulated by growth factors such as Transforming growth factor beta and Fibroblast growth factor families and communicates with extracellular matrix components like Integrin beta1.

Clinical significance and diseases

Aberrations in EGFR are implicated in malignancies including non-small cell lung carcinoma, glioblastoma multiforme, colorectal cancer, head and neck squamous cell carcinoma, and pancreatic adenocarcinoma. Oncogenic mechanisms involve mutations first cataloged by teams at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute, amplifications observed in cohorts from MD Anderson Cancer Center, and rearrangements characterized by investigators at Fred Hutchinson Cancer Research Center. EGFR also features in non-malignant conditions such as pulmonary fibrosis studied at Mount Sinai Health System and dermatological disorders managed at American Academy of Dermatology clinics.

Therapeutic targeting and drug resistance

Targeted therapies include monoclonal antibodies like cetuximab and panitumumab developed by pharmaceutical companies including ImClone Systems and Amgen, and small-molecule tyrosine kinase inhibitors such as gefitinib, erlotinib, afatinib, osimertinib produced by firms like AstraZeneca, Roche, and Astellas. Clinical trials overseen by organizations such as National Cancer Institute and European Medicines Agency defined efficacy and safety profiles. Resistance mechanisms include secondary mutations (e.g., T790M), bypass signaling via MET amplification, histologic transformation to small cell lung cancer, and phenotypic changes described in studies from Broad Institute and Cold Spring Harbor Laboratory. Combination strategies integrating inhibitors with agents targeting PD-1, CTLA-4, or angiogenesis regulators from trials at Johns Hopkins and Vanderbilt University Medical Center are active research areas.

Research methods and model systems

Key methods include crystallography at facilities like Advanced Photon Source, cryo-EM at Electron Bio-Imaging Centre, mass spectrometry at Proteomics Standards Initiative collaborators, and live-cell imaging from groups at Max Planck Institute for Molecular Cell Biology and Genetics. Model systems encompass cultured cell lines from repositories such as ATCC, genetically engineered mouse models from Jackson Laboratory, patient-derived xenografts developed at Huntsman Cancer Institute, and organoid systems pioneered at Hubrecht Institute and Hubrecht Organoid Technology. High-throughput screens performed at Broad Institute and computational analyses using resources from European Bioinformatics Institute drive discovery.

Category:Receptor tyrosine kinases